Top Markets
#1 Ontology Gas Ontology Gas +45.07%
#2 Anvil Anvil +19.32%
#3 ETHGas ETHGas +19.07%
#4 Status Status +18.81%
#5 The Black Bull The Black Bull +17.02%
#6 Geodnet Geodnet +16.47%
#7 Fake World Assets Fake World Assets +13.85%
#8 Derive Derive +10.68%
#9 Ontology Ontology +9.78%
#10 Gas Gas +9.27%
Coin of the day
Ontology Gas Ontology Gas
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Clasificación en acciones #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Precio por acción
$9.81
Última sincronización: 2025-03-18
Capitalización bursátil
$48.68M
Cambio (1 día)
1.55%
Cambio (1 año)
0.00%
País
US
Comercio AlloVir, Inc. (ALVR)

Categoría

Healthcare
Ingresos de AlloVir, Inc. (ALVR)
Ingresos en Jun 2026 TTM: 0.00
Según los últimos informes financieros de AlloVir, Inc., los ingresos actuales de la empresa (TTM) son 0.00. En 2023, la empresa obtuvo unos ingresos de 0.00 igual a los ingresos del año 2022, que fueron de 0.00. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de AlloVir, Inc. desde 2018 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $165.00K -85.46%
2018 $1.14M 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US